Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT

Core Insights - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized as a promising biotech stock with significant potential, supported by a Buy rating and a price target of $145.00 from Piper Sandler [1] Financial Performance - In fiscal Q2 2025, Soleno Therapeutics reported a cash usage of $12.6 million in operating activities for the three months ending June 30, 2025 [2] - The company had $293.8 million in cash, cash equivalents, and marketable securities at the end of Q2 2025, excluding $230 million raised from a common stock offering in July [2] Revenue Generation - The net product revenue for Soleno Therapeutics in the reported quarter reached $32.7 million [3] - The company is focused on developing therapeutics for rare diseases, particularly neurobehavioral and metabolic disorders, with its lead candidate being Diazoxide Choline Controlled-Release (DCCR) for Prader-Willi Syndrome [3]